PCI后强效P2Y12抑制剂单药治疗对比双联抗血小板治疗在STEMI与非STEMI患者中的差异:NEO-MINDSET子研究
NEO-MINDSET预设分析比较ACS患者PCI后早期停用阿司匹林改用强效P2Y12抑制剂单药与标准DAPT的疗效差异。共纳入3410例,其中STEMI 2119例(62.1%),NSTE-ACS 1291例(37.9%)。STEMI患者中单药治疗1年缺血复合终点发生率高于DAPT(8.2% vs 5.2%,HR 1.60,95%CI 1.14-2.24),而NSTE-ACS患者中两组缺血事件率相似(5.1% vs 6.0%,HR 0.84,95%CI 0.53-1.35,交互P=0.030)。两组出血终点在STEMI和NSTE-ACS中均低于DAPT。
要点
- STEMI患者PCI后早期停用阿司匹林改用强效P2Y12抑制剂单药可能增加缺血事件风险。
- NSTE-ACS患者中强效P2Y12抑制剂单药治疗缺血事件率与DAPT相似且出血减少。
- 治疗效应存在ACS类型交互作用(交互P=0.030),需按ACS类型个体化选择抗血小板策略。
核心结论
- STEMI患者PCI后早期停用阿司匹林可能有害,因增加缺血事件风险。
- NSTE-ACS患者中强效P2Y12抑制剂单药治疗可能是可行选择:缺血事件率与DAPT相似且出血减少。
研究设计与样本
- NEO-MINDSET试验的预设分析,随机对照试验子研究。
- 纳入3410例ACS患者,其中STEMI 2119例(62.1%),NSTE-ACS 1291例(37.9%)。
- 随机分为住院4天内启动强效P2Y12抑制剂单药治疗组与标准DAPT(阿司匹林联合强效P2Y12抑制剂)12个月组。
主要发现
- STEMI患者中单药治疗1年缺血复合终点发生率8.2% vs DAPT 5.2%(HR 1.60,95%CI 1.14-2.24)。
- NSTE-ACS患者中单药治疗与DAPT缺血事件率相似(5.1% vs 6.0%,HR 0.84,95%CI 0.53-1.35;交互P=0.030)。
- 出血终点单药治疗在STEMI(HR 0.37,95%CI 0.22-0.61)和NSTE-ACS(HR 0.45,95%CI 0.23-0.86)中均低于DAPT(交互P=0.650)。
关键数值与推荐
- 缺血复合终点包括全因死亡、心肌梗死、卒中和紧急靶血管血运重建。
- 出血终点为BARC 2、3或5型出血。
- NSTE-ACS定义为不稳定心绞痛或非ST段抬高型心肌梗死。
临床怎么用
- STEMI患者PCI后不建议早期停用阿司匹林改用强效P2Y12抑制剂单药,以免增加缺血风险。
- NSTE-ACS患者PCI后可考虑强效P2Y12抑制剂单药治疗作为DAPT的替代选择,以降低出血风险且不增加缺血事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effects of very early aspirin withdrawal with potent P2Y12 inhibitor monotherapy after percutaneous coronary intervention may differ based on acute coronary syndrome (ACS) presentation. OBJECTIVES: This prespecified analysis from the NEO-MINDSET trial evaluated whether treatment effects of early aspirin discontinuation differ between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS; defined as unstable angina or non-ST-segment elevation myocardial infarction). METHODS: NEO-MINDSET randomized ACS patients to potent P2Y12 inhibitor monotherapy initiated within 4 days of hospitalization vs standard dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor for 12 months. Co-primary outcomes were: 1) the composite of all-cause death, myocardial infarction, stroke, and urgent target vessel revascularization (ischemic outcome); and 2) Bleeding Academic Research Consortium types 2, 3, or 5 bleeding (bleeding outcome). RESULTS: Of the 3,410 participants included, 2,119 (62.1%) presented with STEMI and 1,291 (37.9%) with NSTE-ACS. Among STEMI patients, an early aspirin-free strategy was associated with a higher rate of the co-primary ischemic composite outcome compared with DAPT at 1 year (8.2% vs 5.2%, respectively; HR: 1.60; 95% CI: 1.14-2.24), whereas among those with NSTE-ACS, ischemic event rates were similar between monotherapy and DAPT (5.1% vs 6.0%, respectively; HR: 0.84; 95% CI: 0.53-1.35; P for interaction = 0.030). The co-primary bleeding outcome was lower with monotherapy than with DAPT in both STEMI (HR: 0.37; 95% CI: 0.22-0.61) and NSTE-ACS (HR: 0.45; 95% CI: 0.23-0.86) populations (P for interaction = 0.650). CONCLUSIONS: In patients with STEMI treated with percutaneous coronary intervention, early aspirin withdrawal may be harmful, because it increases the risk of ischemic events. Conversely, in NSTE-ACS, potent P2Y12 inhibitor monotherapy may be a viable therapeutic option: Ischemic event rates were similar and bleeding was reduced compared with DAPT. (Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes [NEOMINDSET]; NCT04360720).
引用
- Tavares, Guimarães, Franken, et al. Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. J Am Coll Cardiol. 2025. PMID: 41384891. doi:10.1016/j.jacc.2025.10.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。